

EXPRESS MAIL NO. EL615487546US
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Jiangchun Xu et al.
Filed : February 9, 2001
For : COMPOSITIONS AND METHODS FOR THERAPY
AND DIAGNOSIS OF PROSTATE CANCER
Docket No. : 210121.427C24

Box Patent Application
Assistant Commissioner for Patent
Washington, DC 20231

31025 U.S. PTO
09/780669
02/09/01

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached Forms PTO-1449. This application is a continuation-in-part and relies, under 35 U.S.C. § 120, on the earlier filing date of prior USAN 09/759,143, filed January 12, 2001; which is a continuation-in-part of Application No. 09/685,166, filed October 10, 2000; which is a continuation-in-part of Application No. 09/679,426, filed October 2, 2000, which is a continuation-in-part of Application No. 09/657,279, filed September 6, 2000, which is a continuation-in-part of Application No. 09/651,236, filed August 29, 2000, which is a continuation-in-part of Application No. 09/636,215, filed August 9, 2000; which is a continuation-in-part of Application No. 09/605,783, filed June 27, 2000; which is a continuation-in-part of Application No. 09/593,793, filed June 13, 2000; which is a continuation-in-part of Application No. 09/570,737, filed May 12, 2000; which is a continuation-in-part of Application No. 09/568,100, filed May 9, 2000; which is a continuation-in-part of Application No. 09/536,857, filed March 27, 2000; which is a continuation-in-part of Application No. 09/483,672, filed January 14, 2000; which is a continuation-in-part of Application No. 09/443,686, filed November 18, 1999, which is a continuation-in-part of Application No. 09/439,313, filed November 12, 1999; which is a continuation-in-part of Application No. 09/352,616, filed on July 13, 1999; which is a continuation-in-part of Application No. 09/288,946, filed April 9, 1999; which is a continuation-in-part of Application No. 09/232,149, filed January 15, 1999; which is a continuation-in-part of Application No. 09/159,812, filed September 23, 1998; which is a continuation-in-part of Application No. 09/115,453, filed July 14, 1998; which is a continuation-in-part of Application No. 09/030,607, filed February 25, 1998; which is a continuation-in-part of Application No.


09/020,956, filed February 9, 1998; which is a continuation-in-part of Application No. 08/904,804, filed August 1, 1997; which is a continuation-in-part of Application No. 08/806,099, filed February 25, 1997. The references listed on the attached Forms PTO-1449 were submitted to and/or cited by the Patent and Trademark Office in these prior applications and, therefore, are not required to be provided in this application. If the Examiner wishes, copies will be provided upon request.

As to any reference made of record on the attached Forms PTO-1449, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Jane E. R. Potter

Registration No. 33,332

JEP:jto

Enclosures:

Postcard

Forms PTO-1449 (5 sheets)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

Wpn 210121 - Corixa 427c24 Jds 427c24.sta.doc

FORM PTO 1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.427C24EXPRESS MAIL NO.
EI.615487546US**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

APPLICANTS
Jiangchun Xu et al.FILING DATE
February 9, 2001GROUP PART I/II
Not Yet Assigned**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,786,148	07/28/98	Bandman et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AB	DE 19649207	11/27/96	Germany		X
	AC	EP 317 141 A2	05/24/89	EPO		
	AD	EP 652 014 A1	5/10/95	EPO		
	AE	EP 936 270 A2	08/18/99	EPO		X
	AF	WO 93/14755	08/05/93	PCT		
	AG	WO 93/25224	12/23/93	PCT		
	AH	WO 94/09820	05/11/94	PCT		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AI	Ahn and Kunkel, "The structural and functional diversity of dystrophin," <i>Nature Genetics</i> 3: 283-291, April, 1993.
	AJ	Alexeyev et al., "Improved antibiotic-resistance gene cassettes and omega elements for <i>Escherichia coli</i> vector construction and in vitro deletion/insertion mutagenesis," <i>Gene</i> 160:63-67, 1995.
	AK	Berthon et al., "Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43," <i>Am. J. Hum. Genet.</i> 62(6):1416-1424, June 1998.
	AL	Blok et al., "Isolation of cDNA that are differentially expressed between androgen-dependent and androgen-independent prostate carcinoma cells using differential display PCR," <i>The Prostate</i> 26:213-224, 1995.
	AM	Busselmakers et al., Genbank Accession No. AF103907, August 14, 2000.
	AN	Busselmakers et al., Genbank Accession No. AF103908, August 14, 2000.
	AO	Cawthon et al., "cDNA sequence and genomic structure of EVI2B, a gene lying within an intron of the neurofibromatosis type 1 gene," <i>Genomics</i> 9:446-460, 1991.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

PTO
JAN 10 2001
02/09/01

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.427C24EXPRESS MAIL NO.
EL615487546US**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

APPLICANTS
Jiangchun Xu et al.FILING DATE
February 9, 2001GROUP PART UNIT
Not Yet Assigned**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
----------------------	-----------------	------	------	-------	----------	-------------------------------

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	BA	WO 95/04548	02/16/95	PCT		
	BB	WO 95/14772	06/01/95	PCT (Cover page with English abstract only)		X
	BC	WO 95/30758	11/16/95	PCT		
	BD	WO 96/21671	07/18/96	PCT		
	BE	WO 97/33909	09/18/97	PCT		
	BF	WO 98/12302	03/26/98	PCT		
	BG	WO 98/17687	04/30/98	PCT		
	BH	WO 98/20117	05/14/98	PCT		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	BI	Chu et al., "CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity," <i>J. Exp. Med.</i> 186(10): 1623-1631, November 17, 1997.
	BJ	Coleman et al., <i>Fundamental Immunology</i> , Wm. C. Brown Publishers, Dubuque, Iowa, 1989, pp. 465-466.
	BK	Database EMBL Accession No. AA453562, June 11, 1997, Hillier et al., "Homo sapiens cDNA clone 788180."
	BL	Derwent Geneseq Database, Accession No. V58522, December 8, 1998.
	BM	Derwent Geneseq Database, Accession No. V61287, January 6, 1999.
	BN	Duerst and Nees, "Nucleic acid characteristic of late or early passage cells immortalized by papilloma virus-and related polypeptide(s) and antibodies, used for diagnosis and treatment of cervical cancer and assessing potential for progression of cervical lesions," Derwent World Patent Index, Accession No. 1998-121623, 1998. See also German Patent DE 19649207 C1.
	BO	El-Shirbiny, "Prostatic Specific Antigen, <i>Advances In Clinical Chemistry</i> 31:99-133, 1994.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1447 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.427C24		EXPRESS MAIL NO. EL615487546US	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Jiangchun Xu et al.			
				FILING DATE February 9, 2001		GROUP PART UNIT Not Yet Assigned	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
	CA	WO 98/31799	07/23/98	PCT			
	CB	WO 98/37093	08/27/98	PCT			
	CC	WO 98/37418	08/27/98	PCT			
	CD	WO 98/38310	09/03/98	PCT			
	CE	WO 98/39446	09/11/98	PCT			
	CF	WO 98/45435	10/15/98	PCT			
	CG	WO 98/50567	11/12/98	PCT			
	CH	WO 99/06548	02/11/99	PCT			
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	CI	Ezzell, C., "Cancer vaccines: an idea whose time has come?" <i>The Journal of NIH Research</i> 7:46-49, January, 1995.					
	CJ	Hara et al., "Characterization of cell phenotype by a novel cDNA library subtraction system: expression of CD8 α in a mast cell-derived interleukin-4-dependent cell line," <i>Blood</i> 84(1):189-199, July 1, 1994.					
	CK	Harris et al., "Polycystic Kidney Disease 1: identification and analysis of the primary defect," <i>J. Am. Soc. of Nephrol.</i> 6:1125-1133, 1995.					
	CL	Hillier et al., Genbank Accession No. AA100799, December 23, 1997.					
	CM	Hillier et al., Genbank Accession No. R20590, April 18, 1995.					
	CN	Hudson, T., Genbank Accession No. G22461, May 31, 1996.					
	CO	Kroger, B. "New serine protease from human prostate, useful for identifying specific inhibitors, antibodies and probes," Derwent World Patent Index, Accession No. 99-432218, 1999. See also European Patent EP 936 270 A2.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV. 7-86)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.427C24	EXPRESS MAIL NO. EL615487546US		
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Jiangchun Xu et al.			
				FILED DATE February 9, 2001	GROUP PART UNIT Not Yet Assigned		
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
	DA	WO 99/06552	02/11/99	PCT			
	DB	WO 99/25825	05/27/99	PCT			
	DC	WO 99/31236	06/24/99	PCT			
	DD						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	DE	Lalvani et al., "Rapid effector function in CD8 ⁺ memory cells," <i>J. Exp. Med.</i> 186(6):859-865, September 15, 1997.					
	DF	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA551449, September 5, 1997.					
	DG	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA551759, August 11, 1997.					
	DH	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA631143, October 31, 1997.					
	DI	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA653016, November 25, 1997.					
	DJ	Nelson et al., Genbank Accession No. NP_004908, March 18, 2000.					
	DK	Robson et al., "Identification of prostatic androgen regulated genes using the differential display technique," <i>Proceeding of the American Association for Cancer Research Meeting</i> 86, 36: p.266, Abstract No. 1589, 1995.					
	DL	Schena et al., "Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes," <i>Proc. Natl. Acad. Sci. USA</i> 93(19):10614-10619, September 17, 1996.					
	DM	Sherman et al., "Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8," <i>Science</i> 258(5083):815-818, October 30, 1992					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-449
(REV. 7-89)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.427C24EXPRESS MAIL NO.
EL615487546US**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

APPLICANTS
Jiangchun Xu et al.FILING DATE
February 9, 2001GROUP PARTIALITY
Not Yet Assigned**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	EA						
	EB						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
					YES NO
	FC				

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	EF	Short et al., "λ ZAP: a bacteriophage λ expression vector with <i>in vivo</i> excision properties," <i>Nucleic Acids Research</i> 16(15):7583-7600, 1988.
	EG	Sjögren, H., "Therapeutic Immunization Against Cancer Antigens Using Genetically Engineered Cells," <i>Immunotechnology</i> 3: 161-172, 1997.
	EH	Smith et al., "Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search," <i>Science</i> 274(5291), 1371-1374, November 22, 1996.
	EI	Theobald, et al., "Targeting p53 as a general tumor antigen," <i>Proc. Natl. Sci. USA</i> 92(25):11993-11997, December 5, 1995.
	EJ	Tusnady and Simon, "Principles governing amino acid compositions of integral membrane proteins: application to topology prediction," <i>J. Mol. Biol.</i> 283(2):489-506, October 23, 1998.
	EK	Van Tsai et al., "In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells," <i>Critical Reviews in Immunology</i> 18:65-75, 1998.
	EL	Vasmatzis et al., "Discovery of three genes specifically expressed in human prostate by expressed sequence tag database analysis," <i>Proc. Natl. Acad. Sci. USA</i> 95(1):300-304, January 6, 1998.
	EM	Yee et al., "Isolation of tyrosinase-specific CD8 ⁺ and CD4 ⁺ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus," <i>The Journal of Immunology</i> 157(9):4079-4086, November 1, 1996.
	EN	Zitvogel et al., "Eradication of Established Murine Tumors Using a Novel Cell-Free Vaccine: Dendritic Cell-Derived Exosomes," <i>Nature Medicine</i> 4(5): 594-600, May, 1998.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).